| Literature DB >> 33841101 |
Yingying Zhao1,2,3, Shuanglin Wang3,4,5, Xiaopeng Song6, Junliang Yuan6,7, Dong Qi1, Xiaohuan Gu2, Michael Yaoyao Yin8,9, Zhou Han10, Yanbing Zhu1, Zhandong Liu1, Yongbo Zhang1, Ling Wei2, Zheng Zachory Wei2,11.
Abstract
Neurodevelopmental and neurodegenerative diseases (NDDs) with severe neurological/psychiatric symptoms, such as cerebrovascular pathology in AD, CAA, and chronic stroke, have brought greater attention with their incidence and prevalence having markedly increased over the past few years. Causes of the significant neuropathologies, especially those observed in neurological diseases in the CNS, are commonly believed to involve multiple factors such as an age, a total environment, genetics, and an immunity contributing to their progression, neuronal, and vascular injuries. We primarily focused on the studies of glial involvement/dysfunction in part with the blood-brain barrier (BBB) and the neurovascular unit (NVU) changes, and the vascular mechanisms, which have been both suggested as critical roles in chronic stroke and many other NDDs. It has been noted that glial cells including astrocytes (which outnumber other cell types in the CNS) essentially contribute more to the BBB integrity, extracellular homeostasis, neurotransmitter release, regulation of neurogenic niches in response to neuroinflammatory stimulus, and synaptic plasticity. In a recent study for NDDs utilizing cellular and molecular biology and genetic and pharmacological tools, the role of reactive astrocytes (RACs) and gliosis was demonstrated, able to trigger pathophysiological/psychopathological detrimental changes during the disease progression. We speculate, in particular, the BBB, the NVU, and changes of the astrocytes (potentially different populations from the RACs) not only interfere with neuronal development and synaptogenesis, but also generate oxidative damages, contribute to beta-amyloid clearances and disrupted vasculature, as well as lead to neuroinflammatory disorders. During the past several decades, stem cell therapy has been investigated with a research focus to target related neuro-/vascular pathologies (cell replacement and repair) and neurological/psychiatric symptoms (paracrine protection and homeostasis). Evidence shows that transplantation of neurogenic or vasculogenic cells could be achieved to pursue differentiation and maturation within the diseased brains as expected. It would be hoped that, via regulating functions of astrocytes, astrocytic involvement, and modulation of the BBB, the NVU and astrocytes should be among major targets for therapeutics against NDDs pathogenesis by drug and cell-based therapies. The non-invasive strategies in combination with stem cell transplantation such as the well-tested intranasal deliveries for drug and stem cells by our and many other groups show great translational potentials in NDDs. Neuroimaging and clinically relevant analyzing tools need to be evaluated in various NDDs brains.Entities:
Keywords: astrocyte activation; blood brain barrier; ischemic stroke; local cerebral blood flow; neurovascular unit; vascular neurology; vascular progenitor cells
Year: 2021 PMID: 33841101 PMCID: PMC8032950 DOI: 10.3389/fncel.2021.627682
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
FIGURE 1Glial cells in their gliovascular unit. (A) The star shaped astrocyte (labeled red) with its end feet on the NVU and capillary component. Together with pericytes, astrocytes usually demonstrate the ability to regulate the capillary tone. This type of astrocyte can interact with pericyte or microglia/macrophage at the capillary levels, inducing an intracellular Ca2+ increase via astrocytic P2X. Structures of tripartite synapses are not shown here, consisting of connecting presynaptic and postsynaptic compartments and their enveloping astrocytic process that may facilitate the mechanisms of neurotransmission and astrocytic Gaq/Ga11 GPCR signaling for Ca2+-dependent release of gliotransmitters and synaptic modulation via diacylglycerol kinase and PLD2-AA. (B) For astrocyte-arteriolar molecular crosstalk, the BBB, or at levels of neurovascular coupling, an endothelium vascular active mediator such as NO releases can affect the VSMC layer (labeled orange) such as to cause VSMC relaxation and arteriolar dilation. RBC is not labeled in the graph, but together with endothelial cells that under shear stress release ATP in the vessel to interact with endothelium P2X/P2Y generating/activating AA, cAMP/PGI2, eNOS, PGE2 and EETs. In here, the endothelial receptor may be targeted with acetylcholine, adenosine, ADPs, ATPs, bradykinin, and UTPs activating cAMP/PLA2/PLC, diacylglycerol-AA/EETs/PGI2 to cause VSMC relaxation. Astrocytic/neuronal ATPs are released activating VSMC P2X, P2Y, intracellular Ca2+ to induce VSMC contraction for vasoconstriction.
FIGURE 2Intranasal delivery to bypass the BBB in stroke and ALS. (A) Intranasal delivery of stem cells following cerebral ischemia can show the robust deliveries into the mouse/rat brains. In addition, although not shown here, stem cells intranasally delivered may hold the potentials and repair the vasculature of the brain (Sun et al., 2015). (B) The cells intranasally delivered have demonstrated the ability to reach the spinal cord. Meanwhile, there are many trials on the use of spinally targeted cellular treatment for amyotrophic lateral sclerosis (ALS) or spinal cord injury (SCI), which have reached phase I and phase II clinical stages. Intranasal delivery of drugs such as growth factors or stem cell-derived exosomes have been recently tested in ALS mice models (Zhong et al., 2017; Bonafede et al., 2020).
Brain imaging and general pathological information in acute ischemic stroke.
| Non-contrast computed tomography (NCCT) | Exclude ICH | Ischemia | Regular use of neuroimaging |
| Magnetic resonance imaging (MRI) | Exclude cerebral microbleeds, ICH | Collateral flow | MRI-evident mismatch (diffusion-positive FLAIR-negative lesions) |
| Magnetic resonance angiography (MRA)/Diffusion weighted imaging (DWI) | Selecting candidates for mechanical thrombectomy; Demonstration of LVO stroke | Infarct core and penumbra | |
| CT perfusion (CTP) imaging | For substantial diagnostic uncertainty | ||
| CT angiography (CTA) | Sensitive to LVO stroke | ||
| Digital subtraction angiography (DSA) | Provide critical diagnostic information | Neuro/glio-vasculature | For enhanced diagnostic accuracy |
| Carotid and vertebral/combined duplex | Exclude vessel tortuosity, etc. | Recanalization | Access to intracranial circulation and vasculature |
| Transcranial doppler (TCD) ultrasonography/Transcranial color-coded duplex (TCCD) |
Astrocyte and pericyte biological processes.
| PDGF/PDGFR | Activation, differentiation, recruitment | Endothelial transcytosis barrier, integrity | Angiogenesis, inflammation | |
| Laminins/dystrophin, dystroglycan | Homeostasis | Astrocytic end feet polarization, integrity | Aβ accumulation | |
| ApoE/LRP1 | Loss | Breakdown | Aβ aggregation, microhemorrhages, microinfarct | |
| CXCL12/CXCR4 | Neurotrophic release | Microglia activation, WML | ||
Human astrocyte-based therapeutics and related research.
| Rat PD model, female | TH-transduced astrocytic cell line | Improve motor functions | DOPA and DA release | |
| Rat diabetic model, male | hAMSC, intravenous | Improve BRB integrity | Differentiation into GFAP+ cells | |
| Adult immunodeficient mouse | hESC H7 and H9/hiPSC IMR90-4 lines derived S100β+/GFAP+ cells, intraventricular or intracranial | Form gliovasculature | Differentiation into astrocyte | |
| Adult rat SCI model, female | A2B5–GFAP+ or A2B5+PDGFRa+Nestin+GFAP+hGPC, intraspinal | Fill the injury cavity | Differentiation into astrocyte | |
| Adult mouse/young adult rat ALS model, female/male | hESC HADC100 and NCL14 lines derived GFAP+ cells, intrathecal | Delay disease onset/progression | Neurotrophic factors in the CSF | |
| Adult immunodeficient rat, female/male | Nestin+hNSC NSI-532 line, spinal subpial | Form GFAP+ glia limitans | Differentiation into astrocyte and oligodendrocyte |
Molecular functions of astrocytes based on PPIs with GFAP.